{
    "address": "Industrivagen 19",
    "city": "Solna",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W7S695106",
    "description": "Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. The company is headquartered in Solna, Stockholm. The company went IPO on 2020-11-03. The firm manufactures, markets and sells the prognostic gene test Prostatype. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.",
    "employeeTotal": "",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2020-11-03",
    "isin": "SE0014684569",
    "logo": "",
    "marketCapitalization": 186.9898,
    "naics": "Medical and Diagnostic Laboratories",
    "naicsNationalIndustry": "Medical Laboratories",
    "naicsSector": "Health Care and Social Assistance",
    "naicsSubsector": "Ambulatory Health Care Services",
    "name": "Prostatype Genomics AB",
    "phone": "468208700.0",
    "sedol": "BMCKRR7",
    "shareOutstanding": 13.18687,
    "state": "STOCKHOLM",
    "ticker": "PROGEN.ST",
    "weburl": "https://www.prostatypegenomics.com/"
}